INDAPAMIDE 1.25 MG
INDAPAMIDE : 1.25 MG · DIN 02445824 · SANIS HEALTH INC
Health Canada status: CANCELLED POST MARKET
What is INDAPAMIDE?
INDAPAMIDE 1.25 MG contains INDAPAMIDE : 1.25 MG. It is listed in the Health Canada Drug Product Database under DIN 02445824, held by SANIS HEALTH INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 31-Jul-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02445824 |
|---|---|
| Brand name | INDAPAMIDE |
| Generic / active ingredient | INDAPAMIDE : 1.25 MG |
| Manufacturer | SANIS HEALTH INC |
| Strength | 1.25 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C03BA11 INDAPAMIDE |
| AHFS class | 40:28.24 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 31-Jul-2017 |
| Original market date | 2015-10-14 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code C03BA11 INDAPAMIDE. 4 of 28 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-INDAPAMIDE 1.25 MG TABLETS | 1.25 MG | TABLET | APOTEX INC | MARKETED | DIN 02245246 |
| APO-INDAPAMIDE 2.5MG TABLETS | 2.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02223678 |
| MYLAN-INDAPAMIDE | 1.25 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02240067 |
| MYLAN-INDAPAMIDE | 2.5 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02153483 |
| DOM-INDAPAMIDE TABLETS 1.25MG | 1.25 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02239913 |
| DOM-INDAPAMIDE TABLETS 2.5MG | 2.5 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02239917 |
| INDAPAMIDE | 2.5 MG | TABLET | SANIS HEALTH INC | CANCELLED PRE MARKET | DIN 02365324 |
| INDAPAMIDE | 2.5 MG | TABLET | SANIS HEALTH INC | CANCELLED POST MARKET | DIN 02445832 |
| INDAPAMIDE HEMIHYDRATE 1.25MG - TAB | 1.25 MG | TABLET | PROVAL PHARMA DIVISION OF SERVIER CANADA INC | CANCELLED POST MARKET | DIN 02227339 |
| INDAPAMIDE HEMIHYDRATE TAB 2.5MG | 2.5 MG | TABLET | PROVAL PHARMA DIVISION OF SERVIER CANADA INC | CANCELLED POST MARKET | DIN 02049341 |
Who else supplies INDAPAMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. INDAPAMIDE appears in 129 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.